Clinical study of balloon-occluded retrograde transvenous obliteration for prophylaxis of gastric variceal rebleeding in cirrhosis

BRTO for prophylaxis of gastric variceal rebleeding in cirrhosis

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000033225

Enrollment

Unknown

Registered

2020-05-24

Start date

2020-09-01

Completion date

Unknown

Last updated

2020-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric variceal bleeding

Interventions

BRTO:Treated with BRTO

ECA:Treated with ECA

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) Decompensated liver cirrhosis patients aged 18-80 years; 2) Evidenced gastric variceal bleeding history, with or without esophageal varices. 3) Presence of gastro-renal or gastro-caval shunt.

Exclusion criteria

Exclusion criteria: 1) Complete obstruction of the portal vein; 2) Refractory and massive ascietes; 3) Severe dysfunction of the heart, lungs, liver, kidneys or blood coagulation.

Design outcomes

Primary

Measure	Time frame
Incidence of gastric variceal rebleeding;	—

Secondary

Measure	Time frame
All-cause rebleeding;Times of operation;Cost-effectiveness ratio;	—

Countries

China

Contacts

Public ContactYongjun Zhu

The Second Affiliated Hospital of Chongqing Medical University

hp545204493@126.com+86 13281121937

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026